Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Background: Uncertainty remains regarding the effectiveness of treatments for patients diagnosed with both an alcohol use disorder (AUD) and depressive disorder. This study aimed to compare the effectiveness of clinical interventions for improving symptoms of adults with co-occurring AUDs and depressive disorders. Methods and findings: We searched CINAHL, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Excerpta Medica Database, International Clinical Trials Registry Platform (ICTRP), PubMed, PsycINFO, and Web of Science from inception to December 2020. We included randomized controlled trials (RCTs) evaluating clinical interventions for adults with co-occurring AUDs and depressive disorders. Two independent reviewers extracted study-level information and outcome data. We assessed risk of bias using the Cochrane Risk of Bias tool, used frequentist random effects models for network meta-analyses, and rated our confidence in effect estimates using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Primary outcomes were remission from depression and alcohol use. Secondary outcomes were depressive symptoms, alcohol use, heavy drinking, health-related quality of life, functional status, and adverse events. We used standardized mean differences (SMDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes to estimate intervention effects. Overall, 36 RCTs with 2,729 participants evaluated 14 pharmacological and 4 psychological interventions adjunctive to treatment as usual (TAU). Studies were published from 1971 to 2019, conducted in 13 countries, and had a median sample size of 50 participants (range: 14 to 350 participants). We have very low confidence in all estimates of intervention effects on our primary outcomes (i.e., remission from depression and remission from alcohol use). We have moderate confidence that cognitive behavioral therapies (CBTs) demonstrated greater benefit than no additional treatment (SMD = −0.84; 95% confidence interval [CI], −1.05 to −0.63; p < 0.001) for depressive symptoms and low confidence (SMD = −0.25; 95% CI, −0.47 to −0.04; p = 0.021) for alcohol use. We have low confidence that tricyclic antidepressants (TCAs) demonstrated greater benefit than placebo (SMD = −0.37; 95% CI, −0.72 to −0.02, p = 0.038) for depressive symptoms. Compared with placebo, we have moderate confidence that selective serotonin reuptake inhibitors (SSRIs) demonstrated greater benefit for functional status (SMD = −0.92; 95% CI, −1.36 to −0.47, p < 0.001) and low confidence for alcohol use (SMD = −0.30; 95% CI, −0.59 to −0.02, p = 0.039). However, we have moderate confidence that patients receiving SSRIs also were more likely to experience an adverse event (OR = 2.20; 95% CI, 0.94 to 5.16, p = 0.07). We have very low confidence in all other effect estimates, and we did not have high confidence in any effect estimates. Limitations include the sparsity of evidence on intervention effects over the long term, risks of attrition bias, and heterogeneous definitions of adverse events in the evidence base. Conclusions: We are very uncertain about the existence (or not) of any non-null effects for our primary outcomes of remission from depression and remission from alcohol use. The available evidence does suggest that CBTs likely reduced, and TCAs may have resulted in a slight reduction of depressive symptoms. SSRIs likely increased functional status, and SSRIs and CBTs may have resulted in a slight reduction of alcohol use. However, patients receiving SSRIs also likely had an increased risk of experiencing an adverse event. In addition, these conclusions only apply to postintervention and are not against active comparators, limiting the understanding of the efficacy of interventions in the long term as well as the comparative effectiveness of active treatments. As we did not have high confidence in any outcomes, additional studies are warranted to provide more conclusive evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“some research suggests that combining SSRIs with AUD treatment can yield significant benefits”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
(1992) · PubMed · Cited by 33,716
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · cited 3×
“We prepared the protocol and this report using the relevant Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2015 Statement [15,16], as well as the Methodological Expectations of Cochrane Intervention Reviews [17].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Damschroder, L. J., Aron, D. C., Keith, R. E., Kirsh, S. R., Alexander, J. A., & Lowery, J. C. (2009) · Implementation Science · doi:10.1186/1748-5908-4-50 · Cited by 14,496 · cited 2×
“We collected participant data based on the PRISMA-Equity Extension [25,26], intervention and comparator data using the template for intervention description and replication [27], outcome data using ClinicalTrials.gov criteria for completed defined outcomes [28], study setting data using the Consolidated Framework for…”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Research works printed but not linked: 1
- JPT Higgins, 2016, Methodological Expectations of Cochrane Intervention Reviews
Cited by
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83
“In fact, some research suggests that combining SSRIs with AUD treatment can yield significant benefits, emphasizing the critical importance of addressing both conditions concurrently [60–62].”
BackgroundNicola, M. D., Pepe, M., Panaccione, I., Moccia, L., Janiri, L., & Sani, G. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230403080624 · Cited by 25
“…meta-analysis further confirmed the abovementioned findings, suggesting that treatment with TCAs and Selective Serotonin Reuptake Inhibitors (SSRIs) improves depressive symptoms and functional status in patients dually diagnosed, while effects on drinking outcomes appeared to be less relevant [17].”
ResultFilippis, S. D., Martinotti, G., Nicoletti, F., Mastrostefano, A., Trovini, G., Pugliese, A., & Nicola, M. D. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240827165327 · Cited by 23
“For example, treatment with SSRIs and TCAs improved MDD symptoms bur was less effective in reducing AUD-related symptoms [246].”
Concurrent Disorders and Treatment Outcomes: A Meta-Analysis
Scott, K. D., & Gorey, K. M. (2025) · Journal of Dual Diagnosis · doi:10.1080/15504263.2025.2515015 · Cited by 17
“…Coles et al., 2021; DiFerdinando, 2006; Fitzpatrick-Lewis et al., 2011; Flanagan et al., 2016; Garrod et al., 2020; Glover-Wright et al., 2023; Grant et al., 2021; Hakobyan et al., 2020; Holland & Tickle, 2023; Hunt et al., 2013; Ipser et al., 2015; Issa, 2023; Johnson, 2020; Karapareddy,…”
Alcohol use disorder with comorbid anxiety disorder: a case report and focused literature review
Mocanu, V., & Wood, E. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00344-z · Cited by 14
Metadata
- Authors
- Grant, S., Azhar, G., Han, E., Booth, M., Motala, A., Larkin, J., & Hempel, S.
- Affiliations
- RAND Corporation (US)
- Corresponding author
- Grant, Sean
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-10-08
- Volume
- 18
- Issue
- 10
- Pages
- e1003822
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC8535380
- OpenAlex
- W3117035996
- Cited by
- 31
- References
- 102
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 7 · 2023: 4 · 2022: 3 · 2021: 1
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Update notices
- new_version (2021-10-22)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Defense (Psychological Health Center of Excellence)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- alcoholism, depressive disorders, comorbidities, dual diagnosis, cognitive behavioral therapy, tricyclic antidepressants, selective serotonin reuptake inhibitors, antidepressant augmentation, adjunctive pharmacotherapy, psychological intervention, depression remission, health-related quality of life, functional status, adverse events, treatment effectiveness comparison, adults, treatment-resistant depression, heavy drinking
- MeSH terms
- Adult, Alcoholism, Depression, Female, Humans, Male, Middle Aged, Quality of Life, Remission Induction, Risk, Substance Withdrawal Syndrome, Comorbidity, Publication Bias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1371/journal.pmed.1003822
- The paper
- Grant, S., Azhar, G., Han, E., Booth, M., Motala, A., Larkin, J., & Hempel, S. (2021). Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1003822
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.